Vasomedical, a manufacturer of enhanced external counterpulsation therapy systems, has received the FDA 510(k) clearance to market Vasomedical-Biox 1305 ECG Holter monitor and CB series ambulatory ECG analysis
GlaxoSmithKline has submitted two simultaneous regulatory applications to expand the use of Tyverb/Tykerb. If approved, Tyverb/Tykerb could be used as a first-line therapy regimen combined with anti-hormonal therapy
OXiGENE has initiated a Phase Ib/IIa study of its dual-mechanism, second-generation vascular disrupting agent, OXi4503, in patients with solid tumors with hepatic involvement. The multi-center study is being
XTL Biopharmaceuticals has reported a net loss of $9.25m, or $0.03 per ordinary share, for the year ended December 31, 2008, compared to a net loss of $24.94m,
Mr McCutcheon joins Ventus Medical from Emphasys Medical where he was president and CEO for the past seven years. Previously, Mr McCutcheon was head of sales and marketing
Celsion, a biotechnology company, has reported promising clinical results from its Phase I trial evaluating ThermoDox for the treatment of recurrent chest wall breast cancer. The Phase I
Orthocon’s $25 million financing was co-led by ProQuest Investments and Canaan Partners. The round has also included significant participation from Orthocon’s existing stockholder BB Biotech Ventures. Joyce Tsang,
Pursuant to the settlement, Mylan will have the right to market desloratadine tablets, 5mg, in the US on July 1, 2012, or earlier in certain circumstances, provided that
The grant, which will total $265,000 each year, for the next three years, will be used solely to support and conduct basic and clinical research relating to kidney
Under the terms of the agreement, Cardiovascular Systems will distribute Invatec’s FDA-cleared percutaneous transluminal angioplasty (PTA) balloon catheter product line. The agreement is believed to expand Invatec’s US
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.